HMD
Heramed Ltd
- Announcements, last 12 months
- 57
- Price sensitive, last 12 months
- 16
- Followed on InvestorPA
- Low (Outside the 20% most-followed companies on InvestorPA)
Latest announcements
| Released | Headline | Actions |
|---|---|---|
| Lee Health Approves Expansion of HeraMED Maternity Program Price sensitive | ||
| Trading Halt Price sensitive | ||
| Notification regarding unquoted securities - HMD | ||
| Appendix 4D and Half Year Report Price sensitive | ||
| Resignation and Appointment of Joint Company Secretary | ||
| Quarterly Activities & Cashflow Report Price sensitive | ||
| Change of Director's Interest Notice - TC | ||
| Notification of cessation of securities - HMD | ||
| HeraMED successfully completes Phase 1 pilot with Lee Health Price sensitive | ||
| Notification of cessation of securities - HMD |
Sign in to see all HMD announcements.
Guidance history
| 27 Nov 2025 | The pilot is valued at USD $115,000, encompassing implementation, logistics, patient onboarding, and ongoing technical support, and will be included in the phase 2 deployment upon successful completion of the pilot. | |
| 4 Aug 2025 | The company expects further optimization in research & development functions for the HeraCARE platform with a restructure and transition plan for the technical team about to be finalized and implementation to happen over 2025. This move is part of the company's ongoing commitment to operational efficiency and cost management. | |
| 16 Jun 2025 | The project is expected to generate a trained AI predictive model, which will be commercialized under licensed IP between HeraMED and RMIT/DHCRC. HeraMED's cash contribution to the 18-month project will be approximately $250,000. |
Sign in to see the full guidance history.
Most followed in Health Care
Follow HMD to get its announcements emailed to you, with AI summaries, the full announcement and guidance history, and its most significant announcements.
Sign in